Reply from Louise M. Burke
نویسندگان
چکیده
منابع مشابه
A lifetime in sports nutrition: an interview with Emily Haymes. Interview by Louise M. Burke.
I received my B.A. degree in mathematics and physical education form Drury College in 1961 and my M.S. degree in physical education from Florida State University in December 1962. I took a temporary faculty position at Valparaiso University in 1963 while a faculty member was on a leave of absence. My teaching assignment was physical activity classes (e.g., team sports and swimming). In 1964 I j...
متن کاملDietary studies of athletes: an interview with sports dietitian Bronwen Lundy. Interview by Louise M. Burke.
The articles in this issue of IJSNEM include a dietary survey conducted by Bronwen Lundy and colleagues of professional Australian Rugby League players. As well as providing information on the nutritional practices of these team sport players, this study includes some insight into the techniques of collecting and interpreting dietary information from elite athletes. In this interview, we provid...
متن کاملLOUISE M . RYAN Poisson Regression with Missing Durations of Exposure
D. Y. Lin,’>’>* P. Arbogast,’)’ D. S. S i ~ c o v i c k , ~ ~ ~ and R. N. Lemaitre’ IDepartment of Biostatistics, Box 357232, University of Washington, Seattle, Washington 98195, U.S.A. Cardiovascular Health Research Unit, Department of Medicine, University of Washington, 1730 Minor Avenue, Suite 1360, Seattle, Washington 9810 1, U . S. A. 3Department of Epidemiology, Box 357236, University of ...
متن کاملReply to M. Dhanushkodi
In a letter to the editor in response to our recent article in Journal of Global Oncology titled “Outcomes of Saudi Arabian PatientsWith Nasopharyngeal Cancer Treated With Primarily Neoadjuvant ChemotherapyFollowedbyConcurrentChemoradiotherapy,” Dhanushkodi raises some interesting points. The Meta-Analysis of Chemotherapy in Nasopharynx Carcinoma (MAC-NPC) demonstrated improved overall survival...
متن کاملReply to M. Dhanushkodi
We thankDhanushkodi sincerely for his questions regarding our study, “Cardiovascular Disease Risk Factors:HowRelevant inAfricanMenwithProstate Cancer Receiving Androgen-Deprivation Therapy?” In our facility, the gonadotropin-releasing hormone agonist used is goserelin. The dose administered is 3.6 mg every 28 days subcutaneously until the prostate-specific antigen (PSA) level is 0 ng/mL. Then t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Journal of Physiology
سال: 2017
ISSN: 0022-3751
DOI: 10.1113/jp274011